Position in EXEL
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$1,456,990
+$314,487 QoQ
Shares Held
26,778
+0.5% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Ashton Thomas Private Wealth, LLC holds $8,943,473 across 10 Biotechnology names. EXEL ranks #2 (16.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
35,756 | $4,053,300 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
26,778 | $1,456,990 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,713 | $1,347,628 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
16,184 | $1,266,721 | |
| 5 | LGND |
Ligand Pharmaceuticals Inc
|
1,704 | $538,617 | |
| 6 | CNSY |
Cerenome, Inc.
|
34,306 | $149,917 | |
| 7 | NAUT |
Nautilus Biotechnology, Inc.
|
45,000 | $84,150 | |
| 8 | MRKR |
Marker Therapeutics, Inc.
|
16,400 | $24,108 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,456,990 | 26,778 | Shares | Sole | 2026-07-29 | |
| 2026-03-31 | $1,142,503 | 26,638 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $902,985 | 20,602 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $769,212 | 18,625 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $506,875 | 11,499 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $265,565 | 7,193 | Shares | Sole | 2025-05-16 | |
| 2024-12-31 | $239,726 | 7,199 | Shares | Sole | 2025-02-07 | |
| 2024-06-30 | $6,224 | 277 | Shares | Sole | 2024-08-07 | |
| No filing history on record for this holder in this stock. | ||||||